Skip to content

Speakers

Expand/Collapse

Anderson Clark
Director, Translational In Vivo Pharmacology
EMD Serono Research & Development Institute

Day One

Thursday 13th December 2018

5:30 pm | Close of Conference Day One

8:20 am | Chair's Opening Remarks

Day Two

Thursday 13th December 2018

8:20 am | Chair's Opening Remarks

4:20 pm | Close of Conference

Haluk Yuzugullu
In Vivo Lead, Associate Principal Scientist, IMED
AstraZeneca

Day One

Thursday 13th December 2018

5:05 pm | Q&A - Modelling Cancer Drug Resistance

4:15 pm | PDX-Derived 3D Models to Study Drug Resistance and Novel Combinations

Anna Bunin
Associate Director - Immunology
Kleo Pharmaceuticals Inc.

Chen Zhao
Clinical Fellow
National Institutes of Health

Dan Powell
Director, Clinical Tumor Tissue Facility & Associate Professor
University of Pennsylvania

Day Two

Thursday 13th December 2018

9:45 am | Q&A Panel - Strategy – Selection – Characterization

8:55 am | Models to Understand the Mechanisms of Action of Cancer Biologic Therapies

Daniel Gioeli
Associate Professor
University of Virginia

Davy Ouyang
Executive Director
Crown Bioscience

Day One

Thursday 13th December 2018

10:10 am | Panel Discussion - The Changing Expectations of Model Requirements

8:55 am | Developing Human Target Knock-In Mouse Models for Immuno-Oncology Drug Discovery

Enrique Alvarez
Director - Preclinical Development
Kleo Pharmaceuticals Inc.

Esmaiel Jabbari
Professor
University of South Carolina

Workshop C

July 16, 2019

3:00 pm |
Considerations in Modeling the Microenvironment

Fangxian Sun
Lead Investigator - Research Pharmacology
Sanofi

Day Two

Thursday 13th December 2018

2:30 pm | Moderator Feedback Panel

Geeta Sharma
Scientific Fellow, Translational Research
Tesaro

Day Two

Thursday 13th December 2018

9:45 am | Q&A Panel - Strategy – Selection – Characterization

8:30 am | Preclinical Characterization of TSR-033, A Novel Therapeutic Antibody Targeting LAG-3

Hongmin Chen
Principal Scientist
Merck

Day Two

Thursday 13th December 2018

2:30 pm | Moderator Feedback Panel

Jenni Bernoulli
COO
Pharmatest Services

Alexander Adler
Scientist
Regeneron

Juan Delgado
Lead Data Scientist
Fuel3D

Kader Thiam
Vice President of Transgenic Technologies
genOway

Thiam received a Ph.D. for his work at the department of Cellular Immunology and in Infectious diseases at the Pasteur Institute, Lille (France). Then he was a fellow at The Pasteur Institute, Lille, Department of Peptide Chemistry. His work was focused on the regulation of the immune response by the use of recombinant viruses or synthetic agonist of cytokine, and on the intracellular delivery of lipopeptides modulating pharmacological targets.  Thiam joined genOway, a company specialized in the generation of preclinical in vivo and in vitro models, in 1999. He first joined as Scientific Consultant and Head of the Immunology department. He then served the company as the director of Transgenic Technologies, driving the R&D programs aiming at developing new alternatives to overcome transgenesis limitations and new models for immune response monitoring and better predictability toward human situation. Today, he is the VP of Transgenic Technologies, overseeing feasibility, design, rationale and accuracy of the preclinical models developed by genOway.

Keiji Furuuchi
Associate Director & Head of Immunotherapy & Preclinical Development
Eisai

Kerry Whalen
Director - Discovery & Translational Biology
Tarveda Therapeutics

Lindsey Crowley
Scientist EMD
Serono

Day Two

Thursday 13th December 2018

2:30 pm | Moderator Feedback Panel

Maryland Franklin
Vice President – Scientific Development
MI Bioresearch

Mike Brehm
Professor
University of Massachusetts

Day One

Thursday 13th December 2018

10:10 am | Panel Discussion - The Changing Expectations of Model Requirements

9:20 am | Opportunities & Challenges in Utilizing Humanized Mice to Model Human T Cell Responses

Mithun Khattar
Scientist & Immuno- Oncology Lead
Takeda

Natalia Malkova
Lab Head/ Principal Research Investigator
Sanofi

Natalia Malkova is a principal research investigator in In vivo Pharmacology Group at Sanofi. She received her Ph.D. degree in molecular biology from Engelhardt Institute of Molecular Biology, Russia. She then continued her postdoctoral training in immunology at California Institute of Technology. Interests include cancer immunotherapy, tumor mouse models for preclinical and translational research, tumor microenvironment.

Day One

Thursday 13th December 2018

8:30 am | Local Immunotherapy with Cytokine mRNA Mixture Promotes Potent Anti-Tumor Immunity & Tumor Eradication Across Multiple Preclinical Tumor Models

Neil Michaud
Director, Translational Medicine
EpiZyme

Day One

Thursday 13th December 2018

5:05 pm | Q&A - Modelling Cancer Drug Resistance

4:40 pm | Translation of Preclinical Tumor Modeling of EZH2 Inhibition to Clinical Proof of Concept

Omid Ghasemi
Scientist I, Imaging
Takeda

Rhys Jones
Senior Director DMPK
Pfizer

Day Two

Thursday 13th December 2018

4:00 pm | Q&A Panel – Models Aiding Dose Translation and Understanding Drug Response

3:10 pm | Challenges & Opportunities in Understanding Drug Exposure at The Site Of Action and The Potential Implications of Transporter Mediated Efflux

Rick Huntress
Director of Commercial Business Development
The Jackson Laboratory

Day One

Thursday 13th December 2018

10:10 am | Panel Discussion - The Changing Expectations of Model Requirements

9:45 am | An overview of the JAX Human PDX Tumor Repository

Sarah Knutson
Director, Preclinical Biology
Twentyeight-Seven Therapeutics

Day Two

Thursday 13th December 2018

2:30 pm | Moderator Feedback Panel

Shanthi Ganesh
Associate Director
Dicerna Pharmaceuticals Corp.

Shiva Kazerounian
Associate Director, In Vivo Pharmacology Lead
BRG, LLC

Workshop A

July 16, 2019

11:30 am |
Challenges, Insights & Future Directions for Experimental Models in Cancer Immunotherapy

Shuxi Qiao
Senior Scientist Internal Medicine Research Unit
Pfizer Inc.

Silvia Goldoni
Investigator & Head of Oncology Lab
Novartis

Tseten Jamling
VP of Research and Development
Hera Biolabs

Yvonne Evrard
Operations Manager
Frederick National Laboratory for Cancer Research

Day Two

Thursday 13th December 2018

4:00 pm | Q&A Panel – Models Aiding Dose Translation and Understanding Drug Response

3:35 pm | NCI’s Patient Derived Models Repository Quality Control and Preclinical Efforts